Status:
COMPLETED
Non-Interventional Study With Vinorelbine ORAL in Advanced Non-Small Cell Lung Carcinoma(NSCLC) and Metastatic Breast Cancer (MBC)
Lead Sponsor:
Pierre Fabre Pharma GmbH
Collaborating Sponsors:
iOMEDICO AG
Conditions:
Non Small Cell Lung Carcinoma
Metastatic Breast Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this non-interventional study is to collect data on efficacy and toxicity of the use of Navelbine ORAL in daily routine in Germany (especially after availability of an 80mg capsule). Th...
Eligibility Criteria
Inclusion
- At least 18 years old
- Male and female patients
- Advanced NSCLC (Stage III or IV) or Antracycline-resistant MBC
- Therapy with Navelbine capsules in any palliative treatment line
- Signed patient informed consent
Exclusion
- Pregnancy and nursing
- All other exclusion criteria listed in SPC (summary of product characteristics)
- lack of signed Patient informed consent
Key Trial Info
Start Date :
March 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2012
Estimated Enrollment :
62 Patients enrolled
Trial Details
Trial ID
NCT00890903
Start Date
March 1 2009
End Date
April 1 2012
Last Update
July 2 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pierre Fabre Pharma GmbH
Freiburg im Breisgau, Germany, 79111